Target Recalls Children’s Weighted Blankets After Two Deaths

Retail giant Target Corp (TGT) has recalled about 204,000 Pillowfort weighted blankets for children after two kids died due to asphyxiation.

According to the U.S. Consumer Product Safety Commission, a 4-year-old girl and a 6-year-old girl reportedly became entrapped in the cover of the weighted blanket and died due to asphyxia at Camp Lejeune, North Carolina in April 2022.

Target has received four reports of children becoming entrapped in these weighted blankets, including the two fatalities.

The company said a young child can become entrapped by unzipping and entering the blanket, posing a risk of death by asphyxiation. Target said it was in the process of alerting consumers and urging them to return the product for a full refund.

The recall involves Pillowfort Weighted Blankets, which come in eight prints or colors including unicorn white, space navy, pink, blue, gray, buffalo plaid red, blue constellation, and unicorn pink.

The retailer sold the recalled weighted blankets at its stores nationwide and online from December 2018 through September 2022 for $40.

Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders

Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company’s HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.

EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

The company said this trial brings us one step closer to a new treatment option for underserved cancer patients as there is no specific treatment currently approved for the treatment of skin toxicities associated with EGFRi therapies.

The company added it will advance HT-001 into the clinical phase as it is a key treatment in the onco-dermatology space and anticipates beginning the Phase 2a trial in the first quarter of 2023.

Heron Climbs After Announcing Filing Of SNDA For Zynrelef

Heron Therapeutics, Inc. (HRTX) shares are gaining more than 8 percent after the biotech company announced the filing of an efficacy supplement New Drug Application or sNDA for Zynrelef in soft tissue and orthopedic surgical procedures on Thursday morning trade. The filing is based on safety and pharmacokinetic data trials recently completed in total shoulder arthroplasty, spinal surgery, abdominoplasty, and C-section.

Zynrelef is currently indicated in adults for soft tissue or periarticular instillation.

Currently, shares are at $2.43, up 8.40 percent from the previous close of $2.250 on a volume of 183,847.

Baudax Bio Stock Surges 90%

Shares of Baudax Bio, Inc. (BXRX) are surging nearly 90% on Thursday morning, despite no stock-related statement from the company.

BXRX is currently trading at $4.3699, up $2.0699 or 89.9957%, on the Nasdaq, on a huge volume of 13.0 million shares, above average volume of 1.3 million. The stock opened its trading at $2.1100 after closing previous day at $2.3000. The stock has traded between $0.1210 and $10.0800 in the past 52-week period.

Baudax Bio, a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics.

Cal-Maine Fall Continues

Cal-Maine Foods, Inc. (CALM) shares are sliding more than 11 percent on Thursday morning trade, continuing a bearish trend since December 23 after reaching a year-to-date high. The company’s second-quarter earnings had missed estimates when they announced results yesterday.

Currently, shares are at $55.15, down 11.32 percent from the previous close of $62.19 on a volume of 1,369,999.

Denver metro area school closures for Dec. 29, 2022

On days with severe weather, school closures and government office closures will be updated throughout the day. While most schools are on winter break, a few have announced that offices are closed.

A status of “Other” means there is an early closing or some cancellations — check the website by clicking the name in the list.

To submit closure or delay information to The Denver Post, email [email protected].

Beyond Meat Stock Jumps 10%

Shares of Beyond Meat, Inc. (BYND) are gaining over 10% on Thursday morning after after McDonald’s (MCD) announced the rollout of the Double McPlant across the UK and Ireland.

BYND is currently trading at $12.55, up $1.21 or 10.67%, on the Nasdaq. The stock opened its trading at $11.44 after closing previous day at $11.34. The stock has traded between $11.03 and $74.00 in the past 52-week period.

McDonald’s announced the launch of Double McPlant, in all UK & Ireland restaurants from Wednesday 4th January 2023.

Photos: Winter storm dumps snow across Denver

A winter storm brought heavy snowfall to metro Denver overnight, dropping over seven inches of heavy, wet snow at Denver International Airport by Thursday morning.

The snow began falling late Wednesday evening and began to subside in Denver about 4:30 a.m. Thursday morning; parts of far northeast Colorado will still feel the impacts of the storm through the morning as snow continues to fall out there.

Joint Slips 6% As Removed From S&P SmallCap 600 Index

Shares of Joint Corp. (JYNT) are slipping over 6% on Thursday morning after the company was replaced from S&P SmallCap 600.

JYNT is currently trading at $14.57, down $0.94 or 6.06%, on the Nasdaq. The stock opened its trading at $13.96 after closing previous day at $15.51. The stock has traded between $12.85 and $66.75 in the past 52-week period.

According to S&P Dow Jones Indices, RXO Inc. (RXO) will replace Joint Corp (JYNT) in the S&P SmallCap 600, effective Thursday, January 5, 2023.

The statement said that RXO is more representative of the small-cap market space, and Joint is no longer representative of the small-cap market space.